钠-葡萄糖协同转运蛋白2抑制剂相关临床不良事件:10项随机临床试验及71553例患者的荟萃分析
结果显示SGLT2is增加生殖道感染、尿路感染、糖尿病酮症酸中毒和容量不足风险,但降低严重不良事件、急性肾损伤(AKI)和高钾血症风险;在动脉粥样硬化性心血管疾病(ASCVD)患者中截肢风险较高。
要点
- SGLT2is增加生殖道感染、尿路感染、糖尿病酮症酸中毒和容量不足风险。
- SGLT2is降低严重不良事件、急性肾损伤和高钾血症风险。
- ASCVD患者使用SGLT2is时截肢风险较高,需加强监测。
核心结论
- SGLT2is总体安全,但增加生殖道感染风险,对AKI有保护作用,ASCVD患者截肢风险较高。
研究设计与样本
- 对MEDLINE、EMBASE和Cochrane图书馆检索的随机对照试验进行定量荟萃分析,检索截止2021年1月31日。
主要发现
- 生殖道感染风险比(RR)3.56,95%CI 2.84-4.46。
- 尿路感染RR 1.06,95%CI 1.00-1.12。
- 糖尿病酮症酸中毒RR 2.23,95%CI 1.36-3.63。
- 容量不足RR 1.14,95%CI 1.06-1.23。
- 严重不良事件RR 0.92,95%CI 0.90-0.94;AKI RR 0.84,95%CI 0.77-0.91;高钾血症RR 0.84,95%CI 0.72-0.99。
临床怎么用
- 使用SGLT2is前识别高风险人群,治疗后密切监测不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: SGLT2is are first-line antidiabetic agents with demonstrated cardiovascular benefits. Prior meta-analyses have examined adverse events (AEs) associated with these drugs in general, but such knowledge needs to be updated with the results of more recent trials. In addition, the occurrence of various AEs with different underlying diseases is unknown. OBJECTIVE: This meta-analysis aimed to investigate the occurrence of various AEs associated with sodium-glucose cotransporter 2 inhibitors (SGLT2is) and to examine the level of risk of AEs in patients with different underlying diseases. METHODS: We conducted a quantitative meta-analysis of randomized controlled trials (RCTs) retrieved from the MEDLINE and EMBASE databases and the Cochrane library on January 31, 2021. Outcomes of interest included 4 overall safety outcomes (AEs) and 12 specified safety outcomes. Further analyses were performed on various subgroups, which were defined based on the status of diabetes mellitus (DM), atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease, and congestive heart failure, and by the dosage of SGLT2i (high dose vs low dose). RESULTS: Our analysis included 10 eligible studies with a total of 71 553 participants. The meta-analysis showed that SGLT2i led to increased risks of genital infection (risk ratio [RR] 3.56, 95% CI 2.84-4.46), urinary tract infection (RR 1.06, 95% CI 1.00-1.12), diabetic ketoacidosis (RR 2.23, 95% CI 1.36-3.63), and volume depletion (RR 1.14, 95% CI 1.06-1.23). However, the use of SGLT2i was associated with reduced risks of any serious AE (RR 0.92, 95% CI 0.90-0.94), acute kidney injury (AKI) (RR 0.84, 95% CI 0.77-0.91), and hyperkalemia (RR 0.84, 95% CI 0.72-0.99). Within the different subgroups, the risk of amputation was higher in patients with ASCVD than in those without (RR 1.44 vs 0.96, P = .066). CONCLUSION: The use of SGLT2is is generally safe. SGLT2is may be associated with increased risks of genital infection but are protective against AKI. Of note, the risk of amputation was higher in patients with ASCVD. The key to the safe use of SGLT2is lies in the identification of high-risk populations and close surveillance of patients after treatment.
引用
- Lin DS, Lee JK, Chen WJ, et al. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals. J Clin Endocrinol Metab. 2021. PMID: 33895840. doi:10.1210/clinem/dgab274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。